Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
79°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mind Medicine Mindmed Inc
(NQ:
MNMD
)
7.720
-0.290 (-3.62%)
Streaming Delayed Price
Updated: 3:50 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mind Medicine Mindmed Inc
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Psychedelic Drug Stocks Dragged Down By 83% Collapse In SEEL Stock Price
September 24, 2023
With the 82.6% collapse of Seelos Therapeutics (SEEL) last week, the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index declined by 13.0%, on average, and...
Via
Talk Markets
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
September 18, 2023
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next
Via
Benzinga
Exposures
Product Safety
Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update
September 18, 2023
Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).
Via
Benzinga
4 Of The 6 Largest Psychedelic Compound-Based R & D Stocks Had A Good Week
September 17, 2023
4 of the 6 psychedelic-compound-based research & development stocks in our Psychedelic Drug Stocks Index were up in price last week versus only 1 the previous week. The Index was up 2.4% for the week...
Via
Talk Markets
Analyst Expectations for Mind Medicine's Future
August 22, 2023
Via
Benzinga
What 9 Analyst Ratings Have To Say About Mind Medicine
August 04, 2023
Via
Benzinga
Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows
September 13, 2023
Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined...
Via
Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
MindMed's Phase 2b Trial For MM-120 In GAD Reaches Enrollment Milestone
September 12, 2023
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on pioneering innovative treatments for brain health disorders,
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
6 Largest Psychedelic Compound-Based R & D Stocks In Decline
September 10, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 2.6%, on average, this week and are now only up 6.5% YTD.
Via
Talk Markets
6 Largest Psychedelic Compound-Based R & D Stocks Up 4%, On Average, Last Week
September 05, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were UP 3.9%, on average, last week and are now only UP 9.4% YTD.
Via
Talk Markets
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety
Via
Benzinga
August Recap: Largest Psychedelic Compound-Based R & D Stocks Down 15%
September 02, 2023
The 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were down 15.0%, on average, in August and are now only up 5.3% YTD.
Via
Talk Markets
Psyched: Psilocybin For Gambling Addiction, Ex-NHL Player's Retreat, Fellini's LSD Creativity, Surveys, Financing & More
August 28, 2023
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Via
Benzinga
6 Largest Psychedelic Compound-Based R&D Stocks Continued Downwards, On Average, This Week
August 25, 2023
Only 2 of the 6 psychedelic compound-based research & development stocks in our Psychedelic Drug Stocks Index were up this week.
Via
Talk Markets
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Exposures
Cannabis
Interest Rates
Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend
August 20, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% MTD. We take a look at them in...
Via
Talk Markets
MindMed Inks $50M Credit Facility Deal With K2 HealthVentures For An Additional Operational Year
August 14, 2023
Clinical-stage psychedelics biotech MindMed (NASDAQ: MNMD) has secured a new financing source by entering into a $50 million senior secured credit facility with K2 HealthVentures, an alternative...
Via
Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
So Far, August Isn't Kind To 4 Of 6 Constituents In Our Psychedelic Drug Stocks Index
August 13, 2023
The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index are down an average of 11.9% so far in August but are still up YTD.
Via
Talk Markets
MindMed's Q2 2023: One Of Biggest Players In The Space Sustains Faith In LSD's Multiple Path Ahead
August 07, 2023
Clinical-stage psychedelics biotech MindMed’s (NASDAQ: MNMD) unaudited financial results for the quarter ended June 30, 2023 look like this:
Via
Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
July Summary: Largest Psychedelic Compound-Based R&D Stocks Up 16%, On Average
July 30, 2023
All but 1 of the 6 largest psychedelic compound-based research & development stocks advanced in July and are ranked below as to their performances so far in July:
Via
Talk Markets
Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial
July 28, 2023
UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 14% MTD; Now Up 27% YTD
July 23, 2023
The psychedelic compound-based drug research and development sector is UP 13.6% MTD and is now UP 26.6% YTD and this article analyzes the performance of the 6 largest stocks in the Psychedelic Drug...
Via
Talk Markets
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 18, 2023
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.
Via
Benzinga
Psychedelic Compound-Based Drug Stocks Up 12% MTD; Now Up 25% YTD
July 14, 2023
Our Psychedelic Drug Stocks Index is up 12.3% MTD and is now up 25.1% YTD.
Via
Talk Markets
Psychedelic Stocks Jumped 10% Last Week
July 09, 2023
The FDA released a positive draft guidance for developing psychedelic treatments and the 6 largest stocks in the Psychedelic Drug Stocks Index responded accordingly
Via
Talk Markets
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
World's Largest Psychedelics Conference Boasts 12K Attendees
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.